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Abstract
Background: The stromal vascular fraction (SVF) is a heterogeneous cell population derived from the adipose tissue. There is
still a lack of information concerning the characterization of the cell subpopulations constituting the SVF as well as its
mesenchymal and haematopoietic potential. Furthermore there are great variations in its phenotypical characterization.
Methods: Composition of SVF was investigated by FACS analysis, cytological and "in vitro" assays. We studied CD34+
population by combining FACS with human CFC (colony-forming-cell haematopoietic assay). The endothelial fraction was
investigated by quantifying the co-expression of specific markers (CD146, CD105, CD31 and UEA-1). Mesenchymal potential
was assessed by CFU-F assay and cultured AT-MSC were characterized by a 5-color FACS analysis. The multipotent
differentiation potential (osteogenic, adipogenic and chondrogenic) was investigated both at cellular and molecular level.
Results: We identified in the SVF two CD34+ populations with a marked difference in the intensity of antigen expression, the
majority of the cells expressing CD34 at low intensity. Moreover, two CD146+ cell populations were clearly distinguishable in
the SVF:a CD146 dim accounting for 9.9% of the total SVF cells and a CD146+ bright cell population accounting for about 39.3%.
The frequency of CFC clones was comparable with the one reported for peripheral blood. Endothelial cells account for about
7.7% of the SVF cells. AT-MSC differenced in the osteogenic adipogenic and chondrogenic lineage.
Conclusion: The SVF is not a homogeneous cell population, and its final composition could be influenced both by the flow
cytometric technique analysis and the SVF extraction steps. The CFU-F frequency in the SVF was 1/4880, a value about seven
times greater than the data reported for bone marrow. The antigenic profile of AT-MSC was comparable with bone-marrow
derived MSC. AT-MSC were able to differentiate along the osteogenic adipogenic and chondrogenic lineages. The data here
reported, further contribute to the characterization of SVF, a tissue providing an alternative as a source of MSC for clinical
applications.
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Background
Adipose tissue is derived from the embryonic mesoderm
and consists of a supportive stroma containing a heteroge-
neous cell population including smooth muscle cells,
fibroblast, adipocytes, mast-cells and endothelial cells [1-
4]. The stromal vascular fraction (SVF) is a heterogeneous
cell population derived from manipulation of adipose tis-
sue including homogenization, enzymatic digestion, dif-
ferential centrifugation, red blood cells (RBC) lysis and
washing. The SVF contains multipotent adipose tissue-
derived mesenchymal stem cells (AT-MSC). AT-MSC can
be expanded in culture for several passages: the adherent
derived cell population maintains its mesenchymal phe-
notype and its multipotency towards the mesenchymal
lineage and can be potentially used in regenerative medi-
cine. Other investigators have evidenced that those cells
can be differentiated in vitro in several cell types, such as
adipocytes [5], chondrocytes [5,6], osteoblasts [7,8], and
cardiomyocytes [9,10].
In most experimental studies, the SVF is extracted by
applying the protocol developed by Zuk et al [5,11]. In lit-
erature, there is still a lack of information concerning the
characterization of the cell subpopulations constituting
the SVF, its mesenchymal and haematopoietic potential
and, as a consequence, there are great variations in the
phenotypical characterization of the crude SVF. It is the
case of the percentage of CD34+ positive cells detected in
the SVF, that varies among authors from 80% [12] to 3.5%
[11]. Moreover, the panel of antigens used for the SVF
characterization varied among authors: as a result it is dif-
ficult to draw final conclusions on the cell composition of
the SVF.
In this study, we investigated the antigen composition of
the crude SVF by using a multicolour flow cytometric
(FACS) and cytological analysis of the cells. The CD34
antigen expression was investigated on the SVF as well as
on CD34+ purified cells by combining several haemat-
opoietic and non haematopoietic markers. As "in vitro"
evaluation, the colony-forming cell haematopoietic assay
(CFC) was applied to quantify the haematopoietic poten-
tial of SVF cells. The composition of the endothelial cell
fraction was investigated by quantifying the co-expression
of several endothelial markers and the Ulex europaeus
agglutinin 1 (UEA-1) binding.
Expanded AT-MSC cells at passages two was characterized
by applying a 5-color FACS analysis. Their multipotent
differentiation potential was confirmed both at cellular
and molecular level. Finally, the CFU fibroblast assay was
used to evaluate the frequency of mesenchymal progeni-
tors in the SVF fraction.
Methods
SVF isolation and expansion
Cells were obtained after informed consent from the
resection of subcutaneous fat portions from healthy
female donors who underwent breast plastic surgery (n =
6). SVF fraction was separated using a procedure modified
from Zuk et al [5,11]. Briefly, the tissue was digested with
0.075% collagenase in phosphate buffered-saline solu-
tion (PBS) at pH 7.4 for 45 min at 37°C (Cambrex Bio Sci-
ence, Walkerville). Mature adipocytes and connective
tissues were separated from the cell pellet by centrifuga-
tion at 800 ×g, for 10 min at 4°C. The cell pellet was resus-
pended in erythrocyte lysis buffer (155 mM NH4Cl, 10
mM KHCO3, 0.1 mM EDTA) and incubated for 10 min at
room temperature in the dark. The cell suspension was
then filtered through a 100 µm mesh filter (Becton Dick-
inson) and re-suspended in α-MEM/10%FBS. Nucleated
cell count was performed both using trypan blue exclu-
sion test and an automated cell counter (Sysmex K4500,
Horger, CH). A portion of the cells was used for the Col-
ony Forming Unit Fibroblast Assay (CFU-F). For the isola-
tion and expansion of AT-MSC, the remaining cells of the
SVF were plated in T25 flasks in α-MEM/10% FBS at a
density of 100.000 cells/ml. This initial passage of the pri-
mary cell culture was referred to as passage 0 (P0). Cells
were maintained in media until they achieved 75%–90%
confluence. The cells were then replated at a density of
5.000 cells/cm2 in T25 tissue culture flasks. The identity of
AT-MSC cells was defined by using the criteria purposed
by the ISCT committee [13]: adherence to plastic, specific
surface antigen expression and multipotent differentia-
tion potential.
Colony Forming Unit Fibroblast Assay (CFU-F)
The CFU-F assay was used to evaluate the frequency of
mesenchymal progenitors in the SVF [14]. Briefly, cells
from the SVF were resuspended in duplicate in 6-wells tis-
sue culture plates at a final concentration of 10.000 cells/
cm2 in α-MEM/10%FBS and incubated at 37°C, 5% CO2.
After 14 days, the cells were washed with May-Grunwald
Giemsa. Plates were scored under an inverted microscope
(Nikon Eclipse TS100, Japan). Colonies were considered
aggregates of more than 50 cells.
CD34+ cells purification
SVF cells were isolated by using the direct CD34 Progeni-
tor Cell Isolation Kit (Miltenyi Biotec GmbH; Bergisch-
Gladbach, Germany) following the manufacturer's proto-
col. Briefly, the SVF was incubated at 4°C for 30 min with
the FcR blocking reagent and with magnetic microbeads
coated with anti-CD34 primary antibody (QBEND/10).
After washing, CD34+ cells were isolated by slow flow of
cell suspension through a separation column placed in a
magnetic field. To augment CD34+ cell purity, the separa-
tion step was repeated twice.Journal of Translational Medicine 2007, 5:55 http://www.translational-medicine.com/content/5/1/55
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Morphological evaluation of the cells
SVF cells (7 × 104/slide) were spotted on cytospin slides by
using a cytocentrifuge (Cytospin 3, Shandon Scientific
Ltd, England), stained with May-Grunwald Giemsa and
observed by using a Nikon Eclipse 50i microscope.
In vitro differentiation
After primary culture in control medium (α-MEM/10% FBS
+ 50 U/ml Penicillin + 50 µg/ml Streptomycin, BioWhit-
taker, Walkersville, US), we examined the capacity of the
cells to differentiate along osteogenic, adipogenic and
chondrogenic lineage. Osteogenic induction: cells at pas-
sage 2 were plated at a density of 3.1 × 103/cm2 onto 2-
wells chamber slides (BD Biosciences, Franklin Lakes,
US). Cells were incubated in the control medium for one
day to adhere them to the slides and the medium was
replaced with Osteogenic Induction Medium from Osteo-
genic Differentiation Kit (Cambrex Bioscience, Ltd, Switzer-
land). Osteoinductive medium is a basal medium
supplemented with dexamethasone, β-glycerol phosphate
and ascorbic-acid-2-phospahate. On day 21 cells were
fixed in 10% formalin for 30' and then osteogenic differ-
entiation was assessed by incubating the fixed cells 10' in
Alizarin Red S staining, 2% v/v in distilled water.
For the adipogenic induction, confluent cultures were
incubated in Adipogenic Induction medium from Adipo-
genic Differentiation Kit (Cambrex Bioscience), while
control cultures where fed with Adipogenic Maintenance
medium from the same kit. Induction medium contains rh-
Insulin, Dexamethasone, IBMX and Indomethacin,
whereas  maintenance medium contains only rh-Insulin.
Induction was performed by culturing cells 3–4 days in
induction medium, then 1–2 days in maintenance medium
for 3 times. Adipogenesis was assessed by Oil O Red stain-
ing: cells fixed in 10% formalin were incubated in fresh
Oil O Red water solution for 5'.(Fluka, Sigma-Aldrich,
Saint Louis, US).
For the chondrogenic differentiation, AT-MSC were gently
centrifuged in a 15-ml polypropylene conical tube to form
small pellets and cultured 21 days in "differentiation
basal medium" (Chondrogenic differentiation kit, Lonza)
supplemented with 1 mM sodium pyruvate, 0.17 mM
ascorbic acid-2-phosphate, 0.1 µM dexamethasone and
20 µg/ml TGF-β3. Every 3–4 days, cells were fed with fresh
medium. Chondrogenic pellets were fixed in 10% forma-
lin for 1 h at room temperature. Samples were the embed-
ded in paraffin, sections stained with Alcian Blue and
counterstained with Nuclear Fast Red.
RNA isolation and RT-PCR
Induced and uninduced cell layers were rinsed with D-PBS
(BioWhittaker, Walkersville, US) after 21 days of adipo-
genic or osteogenic induction and immediately lysed
using TRIzol (Invitrogen Corp. Carlsbad, CA, US). Total
RNA was isolated using RNeasy Isolation Kit (Qiagen AG,
Hombrechtikon, DE) and 1 µl was reverse-transcribed
using Enhanced AMV Reverse Transcriptase and specific
primers as indicated by the manufacturer (Sigma, Saint
Louis, US). The resulting cDNA was, then, used as a tem-
plate for PCR amplification with RedTaq Ready Mix
(Sigma); the following genes have been inquired: glycer-
aldehydes-3 phosphate dehydrogenase (GAPDH)
(NM_002046, F: 5'-TTCACCACCATGGAGAAGGC-3', R:
5'-GGCATGGACTGTGGTCATGA-3'), Osteocalcin (OSC),
(NM_199173, F: 5'-CATGAGAGCCCTCACA-3', R: 5'-
AGAGCGACACCCTAGAC-3'), Osteopontin(OSP),
(NM_001040060, F: 5'-TTGCTTTTGCCTCCTAGGCA-3',
R: 5'-GTGAAAACTTCGGTTGCTGG-3'), transcription fac-
tor PPARγ (NM_005037, F: 5'-TCAGGTTTGGGCG-
GATGC-3', R: 5'-TCAGCGGGAAGGACTTTATGTATG-3'),
lipoprotein lipase (LPL) (NM_000237, F: 5'-GAGATT-
TCTCTGTATGGCACC-3', R: 5'-CTGCAAATGAGACACTT-
TCTC-3') and fatty acid binding protein 4 (FABP4)
(NM_001442, F: 5'-ATGGGATGGAAAATCAACCA-3', R:
5'-GTGGAAGTGACGCCTTTCAT-3'). All primer
sequences were original and determined through estab-
lished mRNA GeneBank sequences. Glyceraldehydes-3-
phosphate dehydrogenase was used as a control for assess-
ing PCR efficiency. Reactions were performed in a T3000
thermal cycler (Biometra, Göttingen, Germany) for 35
cycles. Results were visualised by gel electrophoresis in
1.5% agarose (Promega, Madison, US) in a TAE buffer
(Invitrogen) and stained with ethidium bromide
(Promega). Reactions were repeated at least twice.
Flow cytometric analysis of SVF cells
SVF cells were stained in quintuplicate with anti-human
monoclonal antibodies against the following antigens:
CD31 (clone 5.6E) and CD271 (clone ME20.4-1.H4)
(FITC labeled), CD15 (clone VIMC6), CD73 (clone AD2),
CD105 (clone 1G2) and CD133 (clone AC133/1) (PE
labeled), CD45 (clone J33) (ECD labeled), CD13 (clone
Immu103.44), CD14 (clone RMO52), CD146 (clone TEA
1/34), CD90 (clone Thy-1/310), (PC5 labeled) and CD34
(clone 581) (PC7 labeled). For the cell viability test, sam-
ples were incubated with 7-AAD. Isotype-matched murine
FITC, PE, PC5, PC7 and ECD conjugated immunoglobu-
lin were used as controls. All the antibodies were pur-
chased by Beckman Coulter except for CD15, CD133
(Miltenyi Biotech, Germany) and CD73 (Becton Dickin-
son). Endothelial cells were further characterized by stain-
ing the cells with CD45, CD146 and 10 ug/ml of Ulex
lecitin (UEA-1 FITC-labelled, Sigma Aldrich) for 1 h at
room temperature in the dark. Huvec cells were used as a
positive control.Journal of Translational Medicine 2007, 5:55 http://www.translational-medicine.com/content/5/1/55
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Flow cytometric analysis of cultured AT-MSC cells
A 5-color flow cytometric analysis was performed on a
Cytomics FC500 cytofluorimeter (Beckman Coulter,
Miami, FL) and data were analyzed with CXP software.
Cells at passages 2 were analyzed for mesenchymal stem
cells markers with the following anti-human monoclonal
antibodies: CD31 (clone 5.6E), CD44 (clone J-174),
CD29 (clone K20) and CD271 (clone ME20.4-1.H4)
(FITC labeled), CD105 (clone 1G2), CD133 (clone
AC133/1), CD166 (clone 3A6) and CD73 (PE labeled),
CD45 (ECD labeled), CD38 (clone LS198-4-3), CD90
and CD13 (PC5 labeled) and CD34 (PC7 labeled). All Ab
were from Beckman Coulter, except CD73 (Becton Dick-
inson), CD133 and CD271 (Miltenyi Biotec). Isotype-
matched antibodies were also used.
Colony-Forming Cell Haematopoietic Assay
The colony-forming cell haematopoietic assay (CFC) was
performed on the crude SVF fraction and on enriched
CD34+ cells after immunoselection from the SVF. Cells
were cultured in Methocult GF H4434 (Stemcell Technol-
ogies Inc., Vancouver, Canada) containing 1% methylcel-
lulose in Iscove's Modified Dulbecco's medium (IMDM),
30% Fetal Bovine Serum, 1% Bovine Serum Albumin, 10
× 10-4 M 2-Mercaptoethanol, 2 mM L-glutamine, 3 U/ml
recombinant human erythropoietin, 50 ng/ml rh Stem
Cell Factor, 10 ng/ml rh GM-CSF and 10 ng/ml rh IL-3.
Briefly, the SVF crude cells were plated in duplicate at a
final concentration of 100.000 cells/ml and the SVF-
CD34+ selected cells were plated at a final concentration
of 10.000 cells/ml in tissue culture plates (Costar, Acton,
MA). Plates were incubated at 37°C in a fully humidified
atmosphere of 5% carbon dioxide and, after 14 days, each
culture plate was examined under an inverted microscope.
Granulocyte-erithrocyte-macrophage-megakariocyte col-
ony-forming units (CFU-GEMM), granulocyte-macro-
phage colony-forming units (CFU-GM) and blast-forming
units erythroid/mix (BFU-E/mix) were identified and
counted using standard criteria. Colonies were considered
aggregates of more than 50 cells.
Results
Isolation and characterization of SVF and AT-MSC cells
The SVF consists of a heterogeneous cell population:
based on the antigen expression, it is possible to individ-
uate a subset of blood-derived cells. CD45 was detected
with great variability on a mean percentage of 9.0 ± 6.9%
of the SVF cells (range 1.5–17.4). The CD14, expressed on
the monocytic lineage, was detected on 10.9 ± 9.6% of the
cells (range 4.1–17.7) and CD13, expressed both on the
early committed progenitors and mature granulocytes and
monocytes was detected in 5.6 ± 3.9% of the cells (range
2.8–8.4). CD90, a marker associated with haematopoietic
stem cells but also on connective tissue, was expressed on
29.2 ± 20.8% of the SVF (range 10.3–49.9). Complete
data are reported in Table 1 and Table 2.
The percentage of SVF cells expressing CD34 has been
reported with great variability among authors
[11,12,15,16]. In the present study, 6.9 ± 3.0% (range
3.4–10.2) of the SVF cells expressed the CD34 antigen.
Haematopoietic progenitor cells are defined by the co-
expression of the CD45+ cell marker: interestingly, when
analyzing the co-expression of this antigen on CD34+
cells, only 2.0 ± 2.2% (range 0.4–3.5) of the CD34+ cells
stained for CD45. 7.0 ± 5.9% (range 2.8–11) of the
CD34+ cells expressed the CD90, a cell marker present on
haematopoietic stem cells [17]. The CD133 cell marker is
co-expressed on a variable percentage of CD34+ haemat-
opoietic progenitor cells, on stem cells [18], on develop-
ing epithelium and on the haemangioblast [19]. In our
cell populations, CD133 was expressed in only a small
percentage of cells on the SVF (1.2 ± 1.5, range 0.40–
3.80). To better characterize the antigenic profile of
CD34+ cell subpopulation, we purified the CD34 cells by
immunomagnetic selection. Cells were then subjected to
FACS analysis and CFU haematopoietic assay. Two
CD34+ cell subpopulations were present in the SVF frac-
tion: a CD34 dim, accounting for about 90% of the
CD34+ cells, and a CD34+ bright cell subpopulation (Fig-
ure 1). Among them, the CD45+ cells are mainly repre-
sented in the CD34 dim subpopulation (11.3%). The
CD133+ is coexpressed by only 0.3% of the CD34+ cells.
It is possible to conclude that only a small percentage of
the SVF cells expressing the CD34+ antigen are haemat-
opoietic progenitors.
Endothelial cell-associated markers, including CD31 [20],
CD105 [21] and CD146 are expressed on SVF cells. The
CD146 [22], a cell marker expressed on mature endothe-
lia, pericytes, endothelial progenitors cells (EPC) and at
low intensity on a subset of activated T lymphocytes [23]
stains 47.1 ± 3.2 of the cells (range 44.8–49.3) As can be
observed in Figure 2, two distinct CD146 dim and CD146
Table 1: percentage of expression of surface antigens on the cells constituting the crude SVF (n = 6)
ANTIGENS CD13 CD14 CD15 CD31 CD34 CD45 CD73 CD90 CD105 CD133 CD146 CD 271
MEAN % 5.6 10.9 2.0 1.8 6.9 9.0 1.6 29.2 24.1 1.2 47.1 0.6
SD 3.9 9.6 1.7 1.5 3.0 6.9 1.5 20.8 22.1 1.5 3.2 0.5Journal of Translational Medicine 2007, 5:55 http://www.translational-medicine.com/content/5/1/55
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bright cell clusters can be clearly distinguished. To finally
confirm that mature endothelial cells are represented in
the SVF, we have stained the cells in triplicate with CD45,
CD146 and UEA-1. The results obtained suggest that it is
possible to identify in the SVF a cell population having an
endothelial phenotype defined as CD45-, CD146+ and
UEA-1+ accounting for about the 7.7% of the total cells.
(Figure 2).
Adherent cells generated after SVF expansion were
observed after 4–7 days in culture. Cells rapidly generate
a monolayer of fibroblastic-like morphology. At the sec-
ond passage cells were analyzed and resulted to be uni-
formly negative (≤ 2%) for haematopoietic CD34, CD38,
CD45, CD133, and non haematopoietic markers CD31
and CD271, and to be positive (≥ 95%) for CD13, CD29,
CD44, CD73, CD90, CD105 and CD166 (Figure 3).
In vitro differentiation and molecular analysis
We evaluated both osteogenic, adipogenic and chondro-
genic potential in AT-MSC at the second passage. For the
osteogenic differentiation, morphological changes
appeared during the second week of subculture. At the
end of the 21-day induction period, some calcium crystals
were clearly visible in the culture. Cell differentiation was
confirmed by Alizarin Red staining. Osteogenic cell induc-
tion was confirmed at the molecular level: induced cells
showed an upregulation of the expression of osteocalcin
and osteopontin genes with RT-PCR assay.
The adipogenic potential was assessed by induction of
confluent AT-MSC at second passage. At the end of the
induction cycles, a consistent cell vacuolation was evident
in the induced cells. Vacuoles brightly stained for fatty
acid with Oil O Red staining. At the molecular level,
FACS analysis of haematopoietic and endothelial cell subsets in the SVF Figure 1
FACS analysis of haematopoietic and endothelial cell subsets in the SVF. (A) CD34+ cells were analyzed in co-expression with 
CD45 and CD133 cell markers on crude SVF cell population (n = 6) and (B) after CD34 cell selection (n = 3).
A
B
Table 2: percentage of co-expression of surface antigens on the cells constituting the crude SVF (n = 6)
ANTIGENS CD45/34 CD45/133 CD34/90 CD34/133 CD105/146 CD31/146 CD31/105 CD31/15 CD31/90 CD90/73
MEAN % 2.0 0.4 7.0 6.8 6.7 1.9 2.4 1.2 2 2.1
SD 2.2 0.1 5.9 0.5 1.2 0.3 0.6 1.1 0.7 0.3Journal of Translational Medicine 2007, 5:55 http://www.translational-medicine.com/content/5/1/55
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induced cells showed differential expression of genes
from the adipogenic pathway (LPL, FABP4 and PPARγ)
(Figure 4).
Chondrogenic potential was assessed by induction of AT-
MSC using the micromass method. Control cells did not
even retain a spheroid shape and showed no specific
staining while induced cells had a strong signal from
Alcian Blue (Figure 5)
Morphology
Morphologic analysis of the SVF revealed the presence of
immature cells together with cells having a more differen-
ciated morphology (Figure 6). May-Grunwald Giemsa
staining (Figure 6, 100×).
Colony Forming Unit Fibroblast and CFC assay
The CFU-F assay was used to evaluate the frequency of
mesenchymal progenitors in the SVF fraction. The esti-
mated frequency of AT-MSC in the SVF was 1 in 4880 ±
1650 SVF cells (range 1826–6774).
To assess the haematopoietic potential of the SFV, the
crude fraction (n = 5) and the CD34+ selected cells (n = 3)
were plated in Methocult GF H4434. The frequency of
haematopoietic colonies was comparable in the two cell
fractions. Overall, the colonies were isolated with the fol-
lowing frequency (per 105 cells): CFU-E, 3.3 ± 8.2 (range
0–20); BFU-E, 3.2 ± 6.0 (range 1–15); CFU-GM, 3.6 ± 8.1
(range 1–20); CFU-GEMM, 5.0 ± 12.3 (0–30). Images of
haematopoietic colonies isolated from SVF are reported in
Figure 7.
Discussion
The aim of this study was the analysis of the SVF and the
derived AT-MSC population by using a cytological, flow-
cytometrical (FACS) and in vitro assay. We speculate some
hypothesis on the reason why, among authors, there are
marked variations in the percentage of detection of differ-
ent cell antigens by FACS: since the SVF is not a homoge-
neous cell population, its final composition could be
influenced both by the FACS technique analysis and the
cellular extraction steps. For the latter, it is likely that the
cells constituting the SVF have different buoyant densities:
mature cells (i.e. mature epithelia) are characterized by an
increased cell density if compared with immature cells. As
a consequence, the centrifugal force, the centrifugation
time and temperature and the resuspension media, could
influence its final composition.
Endothelial cell markers expression on primary SVF cell population Figure 2
Endothelial cell markers expression on primary SVF cell population. The cells represented in the CD146 vs UEA-1 plot are 
CD45-.Journal of Translational Medicine 2007, 5:55 http://www.translational-medicine.com/content/5/1/55
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We found a great variation in the percentage of haemat-
opoietic CD45 cells in the SVF: since each fat cell in white
adipose tissue is in contact with at least one capillary, pro-
viding a vascular network that allows continued growth of
the tissue [24], the variations in CD45 expression could
reflect differences in the vascularization of the starting tis-
sue. Furthermore it is always possible to observe in the
starting material a different level of contamination with
peripheral blood depending from the tissue harvesting
procedure. Moreover, it has been reported that also the
yield and growth characteristics of adipose-derived mes-
enchymal stem cells are affected by the tissue-harvesting
procedure [25].
The variations in the percentage of detection for certain
cell antigens of more than 22 times among authors (it is
the case of CD34+ cells) could be explained in the differ-
ent gating strategies applied during the flow cytometric
characterization. The CD34, a heavily glycosylated type I
transmembrane protein, is expressed on early lymphohae-
matopoietic stem and progenitor cells: since the SVF is
constituted by a portion of haematopoietic as well as
endothelial-derived cells, the CD34+ antigen should be
investigated by the simultaneous expression of other line-
age-associated molecules (i.e. CD45) in order to deter-
mine the origin of CD34+ cells. We identified two CD34+
cell populations characterized by a striking difference in
the intensity of antigen expression, the great majority of
the cells expressing the CD34 at low intensity. Interest-
ingly, the CD133 is co-expressed by CD34+ cells in only
the 6.8% of the cases.
To better investigate the haematopoietic origin of CD34+
cells in the SVF, we enumerate the haematopoietic pro-
genitors by using a CFU in vitro assay. All the types of cell
progenitors were isolated from the SVF: the frequency of
isolation was generally low. If the number of haematopoi-
etic clones is reported to the percentage of CD45+ cells
detected in the SVF, one can estimate the frequency of
CFU related to the haematopoietic cells in the SVF (×
expression of surface markers in AT-MSC cells derived from SVF cells expansion (n = 5) Figure 3
expression of surface markers in AT-MSC cells derived from SVF cells expansion (n = 5).Journal of Translational Medicine 2007, 5:55 http://www.translational-medicine.com/content/5/1/55
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100.000): CFU-E: 36.8; BFU/E: 35.7; CFU-GM: 40.2; CFU-
GEMM: 55.8. It is possible to conclude that the frequency
of haematopoietic clones isolated in the SVF, could be
compared with the data reported for the normal periph-
eral blood [26]. Based on those observations, it is likely
that they could be derived from the peripheral blood cells
circulating in the adipose tissue.
Aiming to investigate the composition of the endothelial
markers in the SVF, we have stained the cells in triplicate
SVF cells spotted on a cytospin slide Figure 6
SVF cells spotted on a cytospin slide. It is possible to observe 
the presence of immature cells (A) together with cells having 
a more differenciated morphology (B). May-Grunwald 
Giemsa staining (100×).
A
B
osteogenic and adipogenic differentiation of adherent cells from SVF culture Figure 4
osteogenic and adipogenic differentiation of adherent cells from SVF culture. A: osteogenic differentiation (Alizarin Red stain-
ing); B: control; C: adipogenic differentiation (Oil O Red staining); D: control (100×). E: gene expression profile of un-induced 
cells compared with cultured ASC following osteogenic and adipogenic induction. GAPDH: glyceraldehide phosphate dehydro-
genase; OSC: osteocalcin; OSP: osteopontin; PPARγ: peroxisome proliferator-activated receptor γ; LPL: lipoprotein lipase; 
FABP4: fatty acid binding protein 4.
AA
A
E A
Induced  Control
A Ȗ
A
chondrogenic differentiation of cultured AT-MSC by micro- mass method Figure 5
chondrogenic differentiation of cultured AT-MSC by micro-
mass method. A: induced cells; B: control; Alcian Blue stain-
ing (20×).Journal of Translational Medicine 2007, 5:55 http://www.translational-medicine.com/content/5/1/55
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with CD45/CD146/UEA-1. The results obtained suggests
that endothelial cells are represented in the SVF account-
ing for about 7.7% of SVF cells.
It is likely that a percentage of endothelial progenitor cells
are also present in the SVF: in vitro, we observed the forma-
tion of cell clones possessing a specific endothelial-like
morphology in the CFU assay, but further specific analysis
must be done (data not shown).
The CD271 LNGFR (low-affinity nerve growth factor
receptor), has been detected on bone marrow stromal
cells, [27,28] follicular dendritic cells [29] and on mesen-
chymal cells involved in mesenchymal-epithelial interac-
tions [30], and it has been recently purposed as a cell
marker for MSC isolation [28]. The presence of CD271 in
the SVF has not been investigated yet: in our experience,
CD271 was detected on 0.6 ± 0.5% of the SVF cells (range
0.2–1.2). We also investigated the expression of CD271
on expanded AT-MSC at second passage: we conclude that
there is no significant variation in the expression of this
cell antigen in AT-MSC expanded cells compared to crude
SVF.
The AT-MSC could be used for cell therapy protocols:
many groups have evidenced that those cells can be differ-
entiated in vitro in several cell types; among them adi-
pocytes [5], chondrocytes [5,6], osteoblasts [7,8], and
cardiomyocytes [9,10]. AT-MSC possess a mesenchymal
phenotype confirmed in our study by applying the mini-
mal criteria for defining multipotent mesenchymal stro-
mal cells as stated by the International Society for Cellular
Therapy [13] both at cellular and molecular level. The
CFU-F assay was used to evaluate the frequency of mesen-
chymal progenitors in the SVF estimating a frequency of
1/4880, a value about seven times greater than the
reported data for bone marrow [31,32] and comparable
with the data reported for umbilical cord blood [31,33].
The SVF already find application in cellular-based proto-
cols for reconstructive surgery [34] and cardiovascular dis-
ease treatment http://www.cytoritx.com/: the data here
reported, further contribute to the characterization of this
cell population, now constituting an alternative as a
source of MSC for clinical applications.
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phase-contrast photomicrographs of haematopoietic clones in Methocult obtained from the SVF Figure 7
phase-contrast photomicrographs of haematopoietic clones in Methocult obtained from the SVF. A: large CFU-GM (50×); B: 
large BFU-E (50×).
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